Detail akcie Reviva Pharm Rg online

Business Summary: Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Reviva Pharmaceuticals Holdings Inc revenues was not reported. Net loss decreased 30% to $16.5M. Lower net loss reflects Research and development - Balancing va decrease of 47% to $9.3M (expense), General and administrative - Balancing decrease of 3% to $5.6M (expense), Other expense decrease of 79% to $34K (expense).